IMR Press / FBL / Volume 18 / Issue 2 / DOI: 10.2741/4139

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Human monoclonal antibodies in cancer therapy: a review of recent developments

Show Less
1 Department of General Surgery, The Second Affiliated Hospital of NanChang University, 330006 Nanchang, Jiangxi, China
Front. Biosci. (Landmark Ed) 2013, 18(2), 765–772;
Published: 1 January 2013

In the last decade, phage-display technology for the generation of monoclonal antibodies (mAbs) has improved significantly. Several novel human mAbs directed to a wide range of targets have been generated for the treatment of common malignancies. These targets include antigens associated with apoptosis, angiogenesis and solid tumors, as well as tumor growth-related antigens, insulin-like growth factor I receptor and hepatocyte growth factor. The safety, pharmacokinetics, and pharmacodynamics of several human mAbs have been evaluated in patients with advanced solid tumors. In conclusion, significant advances in the generation and application of human mAbs in cancer therapy have been made in the last decade.

Monoclonal antibodies
Ab-dependent cellular cytotoxicity
Back to top